Skip to main content
Top
Published in: Acta Neuropathologica Communications 1/2013

Open Access 01-12-2013 | Research

The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ

Authors: Hannu Kalimo, Maciej Lalowski, Nenad Bogdanovic, Ola Philipson, Thomas D Bird, David Nochlin, Gerard D Schellenberg, RoseMarie Brundin, Tommie Olofsson, Rabah Soliymani, Marc Baumann, Oliver Wirths, Thomas A Bayer, Lars NG Nilsson, Hans Basun, Lars Lannfelt, Martin Ingelsson

Published in: Acta Neuropathologica Communications | Issue 1/2013

Login to get access

Abstract

Background

The Arctic mutation (p.E693G/p.E22G)fs within the β-amyloid (Aβ) region of the β-amyloid precursor protein gene causes an autosomal dominant disease with clinical picture of typical Alzheimer’s disease. Here we report the special character of Arctic AD neuropathology in four deceased patients.

Results

Aβ deposition in the brains was wide-spread (Thal phase 5) and profuse. Virtually all parenchymal deposits were composed of non-fibrillar, Congo red negative Aβ aggregates. Congo red only stained angiopathic vessels. Mass spectrometric analyses showed that Aβ deposits contained variably truncated and modified wild type and mutated Aβ species. In three of four Arctic AD brains, most cerebral cortical plaques appeared targetoid with centres containing C-terminally (beyond aa 40) and variably N-terminally truncated Aβ surrounded by coronas immunopositive for Aβx-42. In the fourth patient plaque centres contained almost no Aβ making the plaques ring-shaped. The architectural pattern of plaques also varied between different anatomic regions. Tau pathology corresponded to Braak stage VI, and appeared mainly as delicate neuropil threads (NT) enriched within Aβ plaques. Dystrophic neurites were scarce, while neurofibrillary tangles were relatively common. Neuronal perikarya within the Aβ plaques appeared relatively intact.

Conclusions

In Arctic AD brain differentially truncated abundant Aβ is deposited in plaques of variable numbers and shapes in different regions of the brain (including exceptional targetoid plaques in neocortex). The extracellular non-fibrillar Aβ does not seem to cause overt damage to adjacent neurons or to induce formation of neurofibrillary tangles, supporting the view that intracellular Aβ oligomers are more neurotoxic than extracellular Aβ deposits. However, the enrichment of NTs within plaques suggests some degree of intra-plaque axonal damage including accumulation of hp-tau, which may impair axoplasmic transport, and thereby contribute to synaptic loss. Finally, similarly as the cotton wool plaques in AD resulting from exon 9 deletion in the presenilin-1 gene, the Arctic plaques induced only modest glial and inflammatory tissue reaction.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, et al.: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488: 96–99. 10.1038/nature11283CrossRefPubMed Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, et al.: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488: 96–99. 10.1038/nature11283CrossRefPubMed
2.
go back to reference Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, Farrer M, Hutton M, Lincoln S, Hardy J, et al.: A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 1998, 4: 452–455. 10.1038/nm0498-452CrossRefPubMed Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, Farrer M, Hutton M, Lincoln S, Hardy J, et al.: A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 1998, 4: 452–455. 10.1038/nm0498-452CrossRefPubMed
3.
go back to reference Verkkoniemi A, Kalimo H, Paetau A, Somer M, Iwatsubo T, Hardy J, Haltia M: Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol 2001, 60: 483–492.PubMed Verkkoniemi A, Kalimo H, Paetau A, Somer M, Iwatsubo T, Hardy J, Haltia M: Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol 2001, 60: 483–492.PubMed
4.
go back to reference Shepherd C, McCann H, Halliday GM: Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol 2009, 118: 37–52. 10.1007/s00401-009-0521-4CrossRefPubMed Shepherd C, McCann H, Halliday GM: Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol 2009, 118: 37–52. 10.1007/s00401-009-0521-4CrossRefPubMed
5.
go back to reference Tomidokoro Y, Rostagno A, Neubert TA, Lu Y, Rebeck GW, Frangione B, Greenberg SM, Ghiso J: Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits. Am J Pathol 2010, 176: 1841–1854. 10.2353/ajpath.2010.090636PubMedCentralCrossRefPubMed Tomidokoro Y, Rostagno A, Neubert TA, Lu Y, Rebeck GW, Frangione B, Greenberg SM, Ghiso J: Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits. Am J Pathol 2010, 176: 1841–1854. 10.2353/ajpath.2010.090636PubMedCentralCrossRefPubMed
6.
go back to reference Maat-Schieman M, Roos R, van Duinen S: Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology 2005, 25: 288–297. 10.1111/j.1440-1789.2005.00631.xCrossRefPubMed Maat-Schieman M, Roos R, van Duinen S: Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology 2005, 25: 288–297. 10.1111/j.1440-1789.2005.00631.xCrossRefPubMed
7.
go back to reference Bugiani O, Giaccone G, Rossi G, Mangieri M, Capobianco R, Morbin M, Mazzoleni G, Cupidi C, Marcon G, Giovagnoli A, et al.: Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch Neurol 2010, 67: 987–995. 10.1001/archneurol.2010.178CrossRefPubMed Bugiani O, Giaccone G, Rossi G, Mangieri M, Capobianco R, Morbin M, Mazzoleni G, Cupidi C, Marcon G, Giovagnoli A, et al.: Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch Neurol 2010, 67: 987–995. 10.1001/archneurol.2010.178CrossRefPubMed
8.
go back to reference Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J: Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000, 275: 27110–27116.PubMed Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J: Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000, 275: 27110–27116.PubMed
9.
go back to reference Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, et al.: A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008, 63: 377–387. 10.1002/ana.21321CrossRefPubMed Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, et al.: A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008, 63: 377–387. 10.1002/ana.21321CrossRefPubMed
10.
go back to reference Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, Anderson L, O'Dahl S, Nemens E, White JA, et al.: Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet 1992, 51: 998–1014.PubMedCentralPubMed Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, Anderson L, O'Dahl S, Nemens E, White JA, et al.: Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet 1992, 51: 998–1014.PubMedCentralPubMed
11.
go back to reference Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, et al.: The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001, 4: 887–893. 10.1038/nn0901-887CrossRefPubMed Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, et al.: The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001, 4: 887–893. 10.1038/nn0901-887CrossRefPubMed
12.
go back to reference Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN: Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 2005, 58: 147–150. 10.1002/ana.20524CrossRefPubMed Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, Nilsson LN: Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 2005, 58: 147–150. 10.1002/ana.20524CrossRefPubMed
13.
go back to reference Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, Almkvist O, Graff C, Nordberg A: Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012, 79: 229–236. 10.1212/WNL.0b013e31825fdf18CrossRefPubMed Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, Almkvist O, Graff C, Nordberg A: Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012, 79: 229–236. 10.1212/WNL.0b013e31825fdf18CrossRefPubMed
14.
go back to reference Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, et al.: A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010, 30: 4845–4856. 10.1523/JNEUROSCI.5825-09.2010CrossRefPubMed Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, et al.: A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 2010, 30: 4845–4856. 10.1523/JNEUROSCI.5825-09.2010CrossRefPubMed
15.
go back to reference Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8: 79–84. 10.1038/nn1372CrossRefPubMed Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8: 79–84. 10.1038/nn1372CrossRefPubMed
16.
go back to reference Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440: 352–357. 10.1038/nature04533CrossRefPubMed Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440: 352–357. 10.1038/nature04533CrossRefPubMed
17.
go back to reference Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K, Bird TD, Nochlin D, Schellenberg GD, Wahlund LO, Lannfelt L: Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 2008, 65: 499–505. 10.1001/archneur.65.4.499PubMedCentralCrossRefPubMed Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K, Bird TD, Nochlin D, Schellenberg GD, Wahlund LO, Lannfelt L: Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 2008, 65: 499–505. 10.1001/archneur.65.4.499PubMedCentralCrossRefPubMed
18.
go back to reference Philipson O, Lord A, Lalowski M, Soliymani R, Baumann M, Thyberg J, Bogdanovic N, Olofsson T, Tjernberg LO, Ingelsson M, et al.: The Arctic amyloid-beta precursor protein (AbetaPP) mutation results in distinct plaques and accumulation of N- and C-truncated Abeta. Neurobiol Aging 2012,33(1010):e1011-e1013. Philipson O, Lord A, Lalowski M, Soliymani R, Baumann M, Thyberg J, Bogdanovic N, Olofsson T, Tjernberg LO, Ingelsson M, et al.: The Arctic amyloid-beta precursor protein (AbetaPP) mutation results in distinct plaques and accumulation of N- and C-truncated Abeta. Neurobiol Aging 2012,33(1010):e1011-e1013.
19.
go back to reference Lord A, Englund H, Soderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN: Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J 2009, 276: 995–1006. 10.1111/j.1742-4658.2008.06836.xPubMedCentralCrossRefPubMed Lord A, Englund H, Soderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN: Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J 2009, 276: 995–1006. 10.1111/j.1742-4658.2008.06836.xPubMedCentralCrossRefPubMed
20.
go back to reference Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58: 1791–1800. 10.1212/WNL.58.12.1791CrossRefPubMed Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58: 1791–1800. 10.1212/WNL.58.12.1791CrossRefPubMed
21.
go back to reference Aho L, Pikkarainen M, Hiltunen M, Leinonen V, Alafuzoff I: Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis 2010, 20: 1015–1028.PubMed Aho L, Pikkarainen M, Hiltunen M, Leinonen V, Alafuzoff I: Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis 2010, 20: 1015–1028.PubMed
22.
go back to reference Duyckaerts C, Delatour B, Potier MC: Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118: 5–36. 10.1007/s00401-009-0532-1CrossRefPubMed Duyckaerts C, Delatour B, Potier MC: Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118: 5–36. 10.1007/s00401-009-0532-1CrossRefPubMed
23.
go back to reference Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al.: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012, 8: 1–13. 10.1016/j.jalz.2011.10.007PubMedCentralCrossRefPubMed Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al.: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012, 8: 1–13. 10.1016/j.jalz.2011.10.007PubMedCentralCrossRefPubMed
24.
go back to reference Hyman BT, Trojanowski JQ: Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997, 56: 1095–1097. 10.1097/00005072-199710000-00002CrossRefPubMed Hyman BT, Trojanowski JQ: Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997, 56: 1095–1097. 10.1097/00005072-199710000-00002CrossRefPubMed
25.
go back to reference Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al.: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012, 123: 1–11. 10.1007/s00401-011-0910-3PubMedCentralCrossRefPubMed Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al.: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012, 123: 1–11. 10.1007/s00401-011-0910-3PubMedCentralCrossRefPubMed
26.
go back to reference Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112: 389–404. 10.1007/s00401-006-0127-zPubMedCentralCrossRefPubMed Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112: 389–404. 10.1007/s00401-006-0127-zPubMedCentralCrossRefPubMed
27.
go back to reference Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, Bugiani O, Del-Tredici K, Ferrer I, Gelpi E, et al.: Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008, 18: 484–496.PubMedCentralPubMed Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, Bugiani O, Del-Tredici K, Ferrer I, Gelpi E, et al.: Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008, 18: 484–496.PubMedCentralPubMed
28.
go back to reference Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41: 479–486. 10.1212/WNL.41.4.479CrossRefPubMed Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41: 479–486. 10.1212/WNL.41.4.479CrossRefPubMed
29.
go back to reference Weller RO, Subash M, Preston SD, Mazanti I, Carare RO: Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008, 18: 253–266.CrossRefPubMed Weller RO, Subash M, Preston SD, Mazanti I, Carare RO: Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008, 18: 253–266.CrossRefPubMed
30.
go back to reference Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Nagren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO: PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008, 131: 1845–1853. 10.1093/brain/awn107CrossRefPubMed Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Nagren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO: PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008, 131: 1845–1853. 10.1093/brain/awn107CrossRefPubMed
32.
go back to reference Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, et al.: Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 2010, 117: 85–96. 10.1007/s00702-009-0314-xPubMedCentralCrossRefPubMed Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, et al.: Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 2010, 117: 85–96. 10.1007/s00702-009-0314-xPubMedCentralCrossRefPubMed
33.
go back to reference Atwood CS, Martins RN, Smith MA, Perry G: Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 2002, 23: 1343–1350. 10.1016/S0196-9781(02)00070-0CrossRefPubMed Atwood CS, Martins RN, Smith MA, Perry G: Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 2002, 23: 1343–1350. 10.1016/S0196-9781(02)00070-0CrossRefPubMed
34.
go back to reference Castano EM, Prelli F, Soto C, Beavis R, Matsubara E, Shoji M, Frangione B: The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1–42 in Alzheimer's disease. J Biol Chem 1996, 271: 32185–32191. 10.1074/jbc.271.50.32185CrossRefPubMed Castano EM, Prelli F, Soto C, Beavis R, Matsubara E, Shoji M, Frangione B: The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1–42 in Alzheimer's disease. J Biol Chem 1996, 271: 32185–32191. 10.1074/jbc.271.50.32185CrossRefPubMed
35.
go back to reference Cynis H, Scheel E, Saido TC, Schilling S, Demuth HU: Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 2008, 47: 7405–7413. 10.1021/bi800250pCrossRefPubMed Cynis H, Scheel E, Saido TC, Schilling S, Demuth HU: Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 2008, 47: 7405–7413. 10.1021/bi800250pCrossRefPubMed
36.
go back to reference Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R: Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry 2005, 44: 10810–10821. 10.1021/bi0508237CrossRefPubMed Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R: Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry 2005, 44: 10810–10821. 10.1021/bi0508237CrossRefPubMed
37.
go back to reference Moro ML, Giaccone G, Lombardi R, Indaco A, Uggetti A, Morbin M, Saccucci S, Di Fede G, Catania M, Walsh DM, et al.: APP mutations in the Abeta coding region are associated with abundant cerebral deposition of Abeta38. Acta Neuropathol 2012, 124: 809–821. 10.1007/s00401-012-1061-xCrossRefPubMed Moro ML, Giaccone G, Lombardi R, Indaco A, Uggetti A, Morbin M, Saccucci S, Di Fede G, Catania M, Walsh DM, et al.: APP mutations in the Abeta coding region are associated with abundant cerebral deposition of Abeta38. Acta Neuropathol 2012, 124: 809–821. 10.1007/s00401-012-1061-xCrossRefPubMed
38.
go back to reference Sahlin C, Lord A, Magnusson K, Englund H, Almeida CG, Greengard P, Nyberg F, Gouras GK, Lannfelt L, Nilsson LN: The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem 2007, 101: 854–862. 10.1111/j.1471-4159.2006.04443.xCrossRefPubMed Sahlin C, Lord A, Magnusson K, Englund H, Almeida CG, Greengard P, Nyberg F, Gouras GK, Lannfelt L, Nilsson LN: The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem 2007, 101: 854–862. 10.1111/j.1471-4159.2006.04443.xCrossRefPubMed
39.
go back to reference Qahwash I, He W, Tomasselli A, Kletzien RF, Yan R: Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. J Biol Chem 2004, 279: 39010–39016. 10.1074/jbc.M407101200CrossRefPubMed Qahwash I, He W, Tomasselli A, Kletzien RF, Yan R: Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. J Biol Chem 2004, 279: 39010–39016. 10.1074/jbc.M407101200CrossRefPubMed
40.
go back to reference Russo C, Schettini G, Saido TC, Hulette C, Lippa C, Lannfelt L, Ghetti B, Gambetti P, Tabaton M, Teller JK: Presenilin-1 mutations in Alzheimer's disease. Nature 2000, 405: 531–532. 10.1038/35014735CrossRefPubMed Russo C, Schettini G, Saido TC, Hulette C, Lippa C, Lannfelt L, Ghetti B, Gambetti P, Tabaton M, Teller JK: Presenilin-1 mutations in Alzheimer's disease. Nature 2000, 405: 531–532. 10.1038/35014735CrossRefPubMed
41.
go back to reference Norlin N, Hellberg M, Filippov A, Sousa AA, Grobner G, Leapman RD, Almqvist N, Antzutkin ON: Aggregation and fibril morphology of the Arctic mutation of Alzheimer's Abeta peptide by CD, TEM, STEM and in situ AFM. J Struct Biol 2012, 180: 174–189. 10.1016/j.jsb.2012.06.010PubMedCentralCrossRefPubMed Norlin N, Hellberg M, Filippov A, Sousa AA, Grobner G, Leapman RD, Almqvist N, Antzutkin ON: Aggregation and fibril morphology of the Arctic mutation of Alzheimer's Abeta peptide by CD, TEM, STEM and in situ AFM. J Struct Biol 2012, 180: 174–189. 10.1016/j.jsb.2012.06.010PubMedCentralCrossRefPubMed
42.
go back to reference Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ: Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277: 32046–32053. 10.1074/jbc.M201750200CrossRefPubMed Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ: Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277: 32046–32053. 10.1074/jbc.M201750200CrossRefPubMed
43.
go back to reference Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT Jr: Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 2003, 332: 795–808. 10.1016/S0022-2836(03)00927-6CrossRefPubMed Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT Jr: Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 2003, 332: 795–808. 10.1016/S0022-2836(03)00927-6CrossRefPubMed
44.
go back to reference Paivio A, Jarvet J, Graslund A, Lannfelt L, Westlind-Danielsson A: Unique physicochemical profile of beta-amyloid peptide variant Abeta1–40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers. J Mol Biol 2004, 339: 145–159. 10.1016/j.jmb.2004.03.028CrossRefPubMed Paivio A, Jarvet J, Graslund A, Lannfelt L, Westlind-Danielsson A: Unique physicochemical profile of beta-amyloid peptide variant Abeta1–40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers. J Mol Biol 2004, 339: 145–159. 10.1016/j.jmb.2004.03.028CrossRefPubMed
45.
go back to reference Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L: Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 2004, 10: 1190–1192. 10.1038/nm1123CrossRefPubMed Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L: Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 2004, 10: 1190–1192. 10.1038/nm1123CrossRefPubMed
46.
go back to reference Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE: Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 2007, 103: 334–345.PubMed Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE: Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 2007, 103: 334–345.PubMed
47.
go back to reference Kheterpal I, Lashuel HA, Hartley DM, Walz T, Lansbury PT Jr, Wetzel R: Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry 2003, 42: 14092–14098. 10.1021/bi0357816CrossRefPubMed Kheterpal I, Lashuel HA, Hartley DM, Walz T, Lansbury PT Jr, Wetzel R: Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry 2003, 42: 14092–14098. 10.1021/bi0357816CrossRefPubMed
48.
go back to reference Kirkitadze MD, Kowalska A: Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. Acta Biochim Pol 2005, 52: 417–423.PubMed Kirkitadze MD, Kowalska A: Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. Acta Biochim Pol 2005, 52: 417–423.PubMed
49.
go back to reference Wirths O, Multhaup G, Bayer TA: A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide–the first step of a fatal cascade. J Neurochem 2004, 91: 513–520. 10.1111/j.1471-4159.2004.02737.xCrossRefPubMed Wirths O, Multhaup G, Bayer TA: A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide–the first step of a fatal cascade. J Neurochem 2004, 91: 513–520. 10.1111/j.1471-4159.2004.02737.xCrossRefPubMed
50.
go back to reference Wirths O, Bayer TA: Intraneuronal Abeta accumulation and neurodegeneration: lessons from transgenic models. Life Sci 2012, 91: 1148–1152. 10.1016/j.lfs.2012.02.001CrossRefPubMed Wirths O, Bayer TA: Intraneuronal Abeta accumulation and neurodegeneration: lessons from transgenic models. Life Sci 2012, 91: 1148–1152. 10.1016/j.lfs.2012.02.001CrossRefPubMed
51.
go back to reference Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA: Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 2009, 118: 487–496. 10.1007/s00401-009-0557-5PubMedCentralCrossRefPubMed Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA: Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 2009, 118: 487–496. 10.1007/s00401-009-0557-5PubMedCentralCrossRefPubMed
52.
go back to reference Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30: 572–580. 10.1002/ana.410300410CrossRefPubMed Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30: 572–580. 10.1002/ana.410300410CrossRefPubMed
Metadata
Title
The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ
Authors
Hannu Kalimo
Maciej Lalowski
Nenad Bogdanovic
Ola Philipson
Thomas D Bird
David Nochlin
Gerard D Schellenberg
RoseMarie Brundin
Tommie Olofsson
Rabah Soliymani
Marc Baumann
Oliver Wirths
Thomas A Bayer
Lars NG Nilsson
Hans Basun
Lars Lannfelt
Martin Ingelsson
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Acta Neuropathologica Communications / Issue 1/2013
Electronic ISSN: 2051-5960
DOI
https://doi.org/10.1186/2051-5960-1-60

Other articles of this Issue 1/2013

Acta Neuropathologica Communications 1/2013 Go to the issue